A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Experts Doubt Necessity of Policy Intervention for LLP-Dependent Companies
January 27, 2023
-
REGULATORY Chuikyo Begins Xocova Price Debate under Mega Seller Rule, Weighs Quicker Re-Pricing
January 26, 2023
-
ORGANIZATION PhRMA Poised to Issue 2024 Reform Proposal in Next Few Months: New Japan Chief
January 25, 2023
-
REGULATORY Xocova Might Trigger Mega Seller Price Control Rule for First Time
January 24, 2023
-
REGULATORY Setting “Presumed Efficacy” Criteria Would Be Difficult; Xocova Decision Reasonable: PMDA Chief
January 23, 2023
-
BUSINESS Opdivo Outdistances Keytruda in 2022 with Sales Up 30 Billion Yen YOY: Encise
January 20, 2023
-
REGULATORY Former Minister Nemoto to Initiate Debates on Pharma Policies by Young Lawmakers
January 19, 2023
-
BUSINESS Ex-Sandoz Japan Chief Tapped to Spearhead Nichi-Iko Turnaround
January 18, 2023
-
REGULATORY Ex-Minister Tamura Hightlights Need for Rewarding Innovation towards FY2024 Drug Reform
January 17, 2023
-
ORGANIZATION Japan Pharma Lobbies Look Set to Shift to Okada/Ueno Leadership towards FY2024 Reform
January 17, 2023
-
BUSINESS Alzheimer’s Med Lecanemab Submitted in Japan: Eisai
January 16, 2023
-
REGULATORY Experts Call for Deregulations for Orphan Support, English Dossiers to Foster Biotech Ecosystem
January 16, 2023
-
BUSINESS Daiichi Sankyo Files First Home-Developed mRNA COVID Vaccine in Japan
January 16, 2023
-
BUSINESS Janssen Vows to Offer New Positions for Employees Shown Exit Door: 1st Labor Talks
January 13, 2023
-
REGULATORY PMP, Off-Patent Drug Rules to Be Major Topics for 2024 Reform: MHLW Pharma Management Director
January 12, 2023
-
BUSINESS Eisai Files Alzheimer’s Med Lecanemab in Europe
January 12, 2023
-
ORGANIZATION FPMAJ Chief Poised to Push Rethink of Price Revision Rules towards FY2024 Reform
January 11, 2023
-
BUSINESS Leqembi Likely to Hit Peak Sales after 2030, US$26,500 Price Matches Value: Eisai CEO
January 10, 2023
-
BUSINESS Lecanemab Nabs Accelerated Approval in US, Set to Hit Market Late January
January 10, 2023
-
REGULATORY MHLW Eyes April Proposal to Push Generic Industry Shake-Up: Asst. Vice Minister
January 6, 2023
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…